Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) EBT Margin (2022 - 2025)

Historic EBT Margin for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to 93.43%.

  • TriSalus Life Sciences' EBT Margin fell 607400.0% to 93.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 98.43%, marking a year-over-year increase of 1082100.0%. This contributed to the annual value of 102.07% for FY2024, which is 2185800.0% up from last year.
  • According to the latest figures from Q3 2025, TriSalus Life Sciences' EBT Margin is 93.43%, which was down 607400.0% from 73.94% recorded in Q2 2025.
  • TriSalus Life Sciences' 5-year EBT Margin high stood at 27.44% for Q3 2023, and its period low was 698.57% during Q4 2022.
  • Over the past 4 years, TriSalus Life Sciences' median EBT Margin value was 122.37% (recorded in 2024), while the average stood at 218.0%.
  • Its EBT Margin has fluctuated over the past 5 years, first surged by 5005600bps in 2024, then tumbled by -607400bps in 2025.
  • TriSalus Life Sciences' EBT Margin (Quarter) stood at 698.57% in 2022, then grew by 11bps to 622.93% in 2023, then soared by 80bps to 122.37% in 2024, then increased by 24bps to 93.43% in 2025.
  • Its EBT Margin stands at 93.43% for Q3 2025, versus 73.94% for Q2 2025 and 113.12% for Q1 2025.